Open AccessRitonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis–HIV-co-infected patients in resource-constrained settings
Author(s) -
Andy Gray,
Salim Safurdeen. Abdool Karim,
Tanuja N. Gengiah
Publication year - 2006
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/01.aids.0000202652.49020.94
Subject(s) - medicine , tuberculosis , rifabutin , saquinavir , ritonavir , efavirenz , regimen , nevirapine , intensive care medicine , protease inhibitor (pharmacology) , rifapentine , reverse transcriptase inhibitor , latent tuberculosis , immunology , pharmacology , viral load , mycobacterium tuberculosis , human immunodeficiency virus (hiv) , antiretroviral therapy , pathology , clarithromycin , helicobacter pylori